BACKGROUND & AIMS: Early recognition of patients at risk for Lynch syndrome is critical but often difficult. Recently, a predictive algorithm-the PREMM(1,2) model-has been developed to quantify the risk of carrying a germline mutation in the mismatch repair (MMR) genes MLH1 and MSH2. However, the model's performance in an unselected, population-based colorectal cancer population as well as its performance in combination with tumor MMR testing are unknown. METHODS: We included all colorectal cancer cases from the EPICOLON study, a prospective, multicenter, population-based cohort (n = 1222). All patients underwent tumor microsatellite instability analysis and immunostaining for MLH1 and MSH2, and those with MMR deficiency (n = 91) underwent tumor BRAF V600E mutation analysis and MLH1/MSH2 germline testing. RESULTS: The PREMM(1,2) model with a >/=5% cut-off had a sensitivity, specificity, and positive predictive value (PPV) of 100%, 68%, and 2%, respectively. The use of a higher PREMM(1,2) cut-off provided a higher specificity and PPV, at expense of a lower sensitivity. The combination of a >/=5% cut-off with tumor MMR testing maintained 100% sensitivity with an increased specificity (97%) and PPV (21%). The PPV of a PREMM(1,2) score >/=20% alone (16%) approached the PPV obtained with PREMM(1,2) score >/=5% combined with tumor MMR testing. In addition, a PREMM(1,2) score of <5% was associated with a high likelihood of a BRAF V600E mutation. CONCLUSIONS: The PREMM(1,2) model is useful to identify MLH1/MSH2 mutation carriers among unselected colorectal cancer patients. Quantitative assessment of the genetic risk might be useful to decide on subsequent tumor MMR and germline testing.
BACKGROUND & AIMS: Early recognition of patients at risk for Lynch syndrome is critical but often difficult. Recently, a predictive algorithm-the PREMM(1,2) model-has been developed to quantify the risk of carrying a germline mutation in the mismatch repair (MMR) genes MLH1 and MSH2. However, the model's performance in an unselected, population-based colorectal cancer population as well as its performance in combination with tumor MMR testing are unknown. METHODS: We included all colorectal cancer cases from the EPICOLON study, a prospective, multicenter, population-based cohort (n = 1222). All patients underwent tumor microsatellite instability analysis and immunostaining for MLH1 and MSH2, and those with MMR deficiency (n = 91) underwent tumorBRAFV600E mutation analysis and MLH1/MSH2 germline testing. RESULTS: The PREMM(1,2) model with a >/=5% cut-off had a sensitivity, specificity, and positive predictive value (PPV) of 100%, 68%, and 2%, respectively. The use of a higher PREMM(1,2) cut-off provided a higher specificity and PPV, at expense of a lower sensitivity. The combination of a >/=5% cut-off with tumor MMR testing maintained 100% sensitivity with an increased specificity (97%) and PPV (21%). The PPV of a PREMM(1,2) score >/=20% alone (16%) approached the PPV obtained with PREMM(1,2) score >/=5% combined with tumor MMR testing. In addition, a PREMM(1,2) score of <5% was associated with a high likelihood of a BRAFV600E mutation. CONCLUSIONS: The PREMM(1,2) model is useful to identify MLH1/MSH2 mutation carriers among unselected colorectal cancerpatients. Quantitative assessment of the genetic risk might be useful to decide on subsequent tumor MMR and germline testing.
Authors: F J Couch; M L DeShano; M A Blackwood; K Calzone; J Stopfer; L Campeau; A Ganguly; T Rebbeck; B L Weber Journal: N Engl J Med Date: 1997-05-15 Impact factor: 91.245
Authors: Asad Umar; C Richard Boland; Jonathan P Terdiman; Sapna Syngal; Albert de la Chapelle; Josef Rüschoff; Richard Fishel; Noralane M Lindor; Lawrence J Burgart; Richard Hamelin; Stanley R Hamilton; Robert A Hiatt; Jeremy Jass; Annika Lindblom; Henry T Lynch; Païvi Peltomaki; Scott D Ramsey; Miguel A Rodriguez-Bigas; Hans F A Vasen; Ernest T Hawk; J Carl Barrett; Andrew N Freedman; Sudhir Srivastava Journal: J Natl Cancer Inst Date: 2004-02-18 Impact factor: 13.506
Authors: Rosa M Xicola; Xavier Llor; Elisenda Pons; Antoni Castells; Cristina Alenda; Virgínia Piñol; Montserrat Andreu; Sergi Castellví-Bel; Artemio Payá; Rodrigo Jover; Xavier Bessa; Anna Girós; José M Duque; David Nicolás-Pérez; Ana M Garcia; Joaquin Rigau; Miquel A Gassull Journal: J Natl Cancer Inst Date: 2007-02-07 Impact factor: 13.506
Authors: M B Loughrey; P M Waring; A Tan; M Trivett; S Kovalenko; V Beshay; M-A Young; G McArthur; A Boussioutas; A Dobrovic Journal: Fam Cancer Date: 2007-04-24 Impact factor: 2.375
Authors: E Lastra; M García-González; B Llorente; C Bernuy; M J Barrio; L Pérez-Cabornero; M Durán; C García-Girón Journal: Clin Transl Oncol Date: 2012-04 Impact factor: 3.405
Authors: Fay Kastrinos; Ewout W Steyerberg; Rowena Mercado; Judith Balmaña; Spring Holter; Steven Gallinger; Kimberly D Siegmund; James M Church; Mark A Jenkins; Noralane M Lindor; Stephen N Thibodeau; Lynn Anne Burbidge; Richard J Wenstrup; Sapna Syngal Journal: Gastroenterology Date: 2010-08-19 Impact factor: 22.682
Authors: Fay Kastrinos; Hajime Uno; Chinedu Ukaegbu; Carmelita Alvero; Ashley McFarland; Matthew B Yurgelun; Matthew H Kulke; Deborah Schrag; Jeffrey A Meyerhardt; Charles S Fuchs; Robert J Mayer; Kimmie Ng; Ewout W Steyerberg; Sapna Syngal Journal: J Clin Oncol Date: 2017-05-10 Impact factor: 44.544
Authors: Leticia Moreira; Francesc Balaguer; Noralane Lindor; Albert de la Chapelle; Heather Hampel; Lauri A Aaltonen; John L Hopper; Loic Le Marchand; Steven Gallinger; Polly A Newcomb; Robert Haile; Stephen N Thibodeau; Shanaka Gunawardena; Mark A Jenkins; Daniel D Buchanan; John D Potter; John A Baron; Dennis J Ahnen; Victor Moreno; Montserrat Andreu; Maurizio Ponz de Leon; Anil K Rustgi; Antoni Castells Journal: JAMA Date: 2012-10-17 Impact factor: 56.272
Authors: Fay Kastrinos; John I Allen; David H Stockwell; Elena M Stoffel; Earl F Cook; Muthoka L Mutinga; Judith Balmaña; Sapna Syngal Journal: Am J Gastroenterol Date: 2009-04-28 Impact factor: 10.864
Authors: Victoria Gonzalo; Juan José Lozano; Jenifer Muñoz; Francesc Balaguer; Maria Pellisé; Cristina Rodríguez de Miguel; Montserrat Andreu; Rodrigo Jover; Xavier Llor; M Dolores Giráldez; Teresa Ocaña; Anna Serradesanferm; Virginia Alonso-Espinaco; Mireya Jimeno; Miriam Cuatrecasas; Oriol Sendino; Sergi Castellví-Bel; Antoni Castells Journal: PLoS One Date: 2010-01-19 Impact factor: 3.240